主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2016, Vol. 39 ›› Issue (6): 520-523.doi: 10.3969/j.issn.1006-2157.2016.06.017

• 临床研究 • 上一篇    下一篇

补肾强骨方治疗多发性骨髓瘤临床观察*

黄智莉1,于天启2,陈亚勇1,郭珊珊2   

  1. 1 广州市中医医院 广东 510130;
    2 广州中医药大学附属第三医院
  • 收稿日期:2016-01-07 出版日期:2016-06-30 发布日期:2016-06-30
  • 作者简介:黄智莉,女,博士,副主任医师
  • 基金资助:
    *广东省中医药管理局课题(No.20141209)

Clinical observation of Bushen Qianggu Decoction on multiple myeloma*

HUANG Zhili1, YU Tianqi2, CHEN Yayong1, GUO Shanshan2   

  1. 1 Guangzhou Hospital of TCM, Guangdong 510130;
    2 Third Hospital of Guangzhou University of TCM
  • Received:2016-01-07 Online:2016-06-30 Published:2016-06-30

摘要: 目的 观察补肾强骨方对多发性骨髓瘤(MM)巨噬细胞移动抑制因子(MIF)的骨髓影响及临床疗效,为临床推广应用提供依据。方法 选择符合纳入标准的多发性骨髓瘤患者30例,随机分为2组,治疗组用补肾强骨方联合VAD化疗方案,对照组用沙利度胺联合VAD化疗方案,观察治疗前后患者血浆MIF水平、血红蛋白、血清M蛋白、骨髓浆细胞比例、血清钙、血β2微球蛋白(β2-MG)、乳酸脱氢酶(LDH)、C-反应蛋白(CRP)指标变化,并统计临床疗效,分析不良反应。结果 治疗组、对照组治疗前后血浆MIF水平、血红蛋白、M蛋白、骨髓浆细胞比例、CRP比较,具有统计学意义,P<0.01;血β2-MG比较,具有统计学意义,P<0.05; 血钙、血LDH比较,无统计学意义,P>0.05。治疗组总有效率达86.66%,对照组总有效率达80%,经Ridit统计分析,无明显差异,P>0.05。治疗过程中便秘、嗜睡、浮肿、外周神经病变的2组比较,有统计学意义,P<0.05。结论 补肾强骨方治疗MM疗效与沙利度胺相似,可以降低血浆MIF水平,提升血红蛋白,降低M蛋白、浆细胞比例、血β2-MG、CRP,且不良反应明显减少。表明补肾强骨方对MM治疗具有一定优势,可抑制MM血浆MIF的高表达、抑制血管新生。

关键词: 补肾强骨方, 多发性骨髓瘤, 巨噬细胞移动抑制因子

Abstract: Objective To observe the effects of Bushen Qianggu Decoction(BQD) on macrophage migration inhibitory factor(MIF) of patients with multiple myeloma(MM)and its clinical efficacy, so as to provide the ground for clinical promotion. Methods 30 patients who accorded with the inclusive criteria were divided into two groups randomly. BQD combined with VAD chemotherapy regimen were used in treatment group; thalidomide combined with VAD chemotherapy regimen were used in control group. The indexes of pre- and post- treatment were observed, including serum MIF, hemoglobin, serum M protein, marrow plasmacyte rate, serum calcium, serum β2 microglobulin (β2-MG) , lactic acid dehydrogenase (LDH), and C-reaction protein (CRP). And the clinical efficacy and adverse reaction were studied. Results There were statistical differences between treatment group and control group in serum MIF,hemoglobin, serum M protein, marrow plasmacyte rate, CRP (P<0.01) and β2-MG (P<0.05). There was no difference in serum calcium and LDH (P>0.05). The total effective rate in treatment group was 86.66% compared to 80% in control group, no significant differences after Ridit analysis (P>0.05). The incidence of constipation, sleepiness, edema, peripheral neuropathy of control group were significantly higher than that of treatment group (P<0.05). Conclusion The clinical efficacy of BQD on MM was close to thalidomide with obviously less adverse reactions. BQD decreased serum MIF, M protein, marrow plasmacyte rate, serum β2-MG, and CRP, increased hemoglobin, and adverse reactions were decreased significantly. This study showed that BQD has certain advantages on MM by the way of inhibiting the high expression of serum MIF and angiogenesis.

Key words: Bushen Qianggu Decoction, multiple myeloma, macrophage migration inhibitory factor

中图分类号: 

  • R273.33